BIOG B Stock Overview
BioGaia AB (publ) develops, markets, and sells probiotic products with documented health benefits worldwide.
No risks detected for BIOG B from our risk checks.
Price History & Performance
|Historical stock prices|
|Current Share Price||kr490.50|
|52 Week High||kr584.00|
|52 Week Low||kr394.50|
|1 Month Change||-3.06%|
|3 Month Change||-3.82%|
|1 Year Change||-3.06%|
|3 Year Change||32.75%|
|5 Year Change||53.52%|
|Change since IPO||1,141.78%|
Recent News & Updates
|BIOG B||SE Biotechs||SE Market|
Return vs Industry: BIOG B exceeded the Swedish Biotechs industry which returned -5.5% over the past year.
Return vs Market: BIOG B underperformed the Swedish Market which returned 15.9% over the past year.
|BIOG B volatility|
|BIOG B Average Weekly Movement||5.0%|
|Biotechs Industry Average Movement||8.2%|
|Market Average Movement||6.7%|
|10% most volatile stocks in SE Market||11.7%|
|10% least volatile stocks in SE Market||3.9%|
Stable Share Price: BIOG B is not significantly more volatile than the rest of Swedish stocks over the past 3 months, typically moving +/- 5% a week.
Volatility Over Time: BIOG B's weekly volatility (5%) has been stable over the past year.
About the Company
|1990||159||Isabelle Valerie Ducellier||https://www.biogaia.com|
BioGaia AB (publ) develops, markets, and sells probiotic products with documented health benefits worldwide. It operates in Pediatrics, Adult Health, and Other segments. The Pediatrics segment offers drops, oral rehydration solutions, and gut health tablets, as well as cultures that are used as an ingredient in infant formula.
BioGaia Fundamentals Summary
|BIOG B fundamental statistics|
Is BIOG B overvalued?See Fair Value and valuation analysis
Earnings & Revenue
|BIOG B income statement (TTM)|
|Cost of Revenue||kr202.68m|
Last Reported Earnings
Sep 30, 2021
Next Earnings Date
Feb 04, 2022
|Earnings per share (EPS)||9.73|
|Net Profit Margin||25.63%|
How did BIOG B perform over the long term?See historical performance and comparison
0.7%Current Dividend Yield
Is BioGaia undervalued compared to its fair value and its price relative to the market?
Price to Earnings (PE) ratio
Share Price vs. Fair Value
Below Fair Value: BIOG B (SEK490.5) is trading above our estimate of fair value (SEK348.94)
Significantly Below Fair Value: BIOG B is trading above our estimate of fair value.
Price To Earnings Ratio
PE vs Industry: BIOG B's PE Ratio (50.4x) is in line with the Swedish Biotechs industry average.
PE vs Market: BIOG B is poor value based on its PE Ratio (50.4x) compared to the Swedish market (22.2x).
Price to Earnings Growth Ratio
PEG Ratio: BIOG B is poor value based on its PEG Ratio (5.4x)
Price to Book Ratio
PB vs Industry: BIOG B is overvalued based on its PB Ratio (5.4x) compared to the SE Biotechs industry average (3.1x).
How is BioGaia forecast to perform in the next 1 to 3 years based on estimates from 2 analysts?
Forecasted annual earnings growth
Earnings and Revenue Growth Forecasts
Analyst Future Growth Forecasts
Earnings vs Savings Rate: BIOG B's forecast earnings growth (9.4% per year) is above the savings rate (0.3%).
Earnings vs Market: BIOG B's earnings (9.4% per year) are forecast to grow faster than the Swedish market (0.7% per year).
High Growth Earnings: BIOG B's earnings are forecast to grow, but not significantly.
Revenue vs Market: BIOG B's revenue (12% per year) is forecast to grow faster than the Swedish market (1.6% per year).
High Growth Revenue: BIOG B's revenue (12% per year) is forecast to grow slower than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: BIOG B's Return on Equity is forecast to be low in 3 years time (11.4%).
How has BioGaia performed over the past 5 years?
Historical annual earnings growth
Earnings and Revenue History
Quality Earnings: BIOG B has high quality earnings.
Growing Profit Margin: BIOG B's current net profit margins (25.6%) are higher than last year (25.3%).
Past Earnings Growth Analysis
Earnings Trend: BIOG B's earnings have grown by 3.1% per year over the past 5 years.
Accelerating Growth: BIOG B's earnings growth over the past year (1.4%) is below its 5-year average (3.1% per year).
Earnings vs Industry: BIOG B earnings growth over the past year (1.4%) underperformed the Biotechs industry 1.4%.
Return on Equity
High ROE: BIOG B's Return on Equity (10.7%) is considered low.
How is BioGaia's financial position?
Financial Position Analysis
Short Term Liabilities: BIOG B's short term assets (SEK1.7B) exceed its short term liabilities (SEK104.1M).
Long Term Liabilities: BIOG B's short term assets (SEK1.7B) exceed its long term liabilities (SEK24.8M).
Debt to Equity History and Analysis
Debt Level: BIOG B is debt free.
Reducing Debt: BIOG B has not had any debt for past 5 years.
Debt Coverage: BIOG B has no debt, therefore it does not need to be covered by operating cash flow.
Interest Coverage: BIOG B has no debt, therefore coverage of interest payments is not a concern.
What is BioGaia current dividend yield, its reliability and sustainability?
Current Dividend Yield
Dividend Yield vs Market
Notable Dividend: BIOG B's dividend (0.7%) isn’t notable compared to the bottom 25% of dividend payers in the Swedish market (1.04%).
High Dividend: BIOG B's dividend (0.7%) is low compared to the top 25% of dividend payers in the Swedish market (3.42%).
Stability and Growth of Payments
Stable Dividend: BIOG B's dividend payments have been volatile in the past 10 years.
Growing Dividend: BIOG B's dividend payments have increased over the past 10 years.
Current Payout to Shareholders
Dividend Coverage: With its reasonably low payout ratio (34.5%), BIOG B's dividend payments are well covered by earnings.
Future Payout to Shareholders
Future Dividend Coverage: BIOG B's dividends in 3 years are forecast to be well covered by earnings (44.8% payout ratio).
How experienced are the management team and are they aligned to shareholders interests?
Average management tenure
Isabelle Valerie Ducellier (52 yo)
Ms. Isabelle Valerie Ghislaine Ducellier serves as the Chief Executive Officer and President of BioGaia AB. Ms. Ducellier has been Partner and Consultant at Anian Ab since 2016. She serves as a Board Membe...
CEO Compensation Analysis
Compensation vs Market: Isabelle Valerie's total compensation ($USD350.47K) is below average for companies of similar size in the Swedish market ($USD627.67K).
Compensation vs Earnings: Isabelle Valerie's compensation has been consistent with company performance over the past year.
Experienced Management: BIOG B's management team is considered experienced (3 years average tenure).
Experienced Board: BIOG B's board of directors are considered experienced (3.8 years average tenure).
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.
Recent Insider Transactions
Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.
BioGaia AB (publ)'s employee growth, exchange listings and data sources
- Name: BioGaia AB (publ)
- Ticker: BIOG B
- Exchange: OM
- Founded: 1990
- Industry: Biotechnology
- Sector: Pharmaceuticals & Biotech
- Implied Market Cap: kr9.906b
- Shares outstanding: 20.20m
- Website: https://www.biogaia.com
Number of Employees
- BioGaia AB (publ)
- Kungsbroplan 3
- Stockholm County
- 112 27
Company Analysis and Financial Data Status
|Data||Last Updated (UTC time)|
|Company Analysis||2022/01/23 18:45|
|End of Day Share Price||2022/01/21 00:00|
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.